Table 1.
Characteristics of CML patients with relapse after allo-SCT
| n, (%) | ||
|---|---|---|
| Sex | Females | 21 (36%) |
| Males | 38 (64%) | |
| Age>40 | Yes | 25 (42%) |
| No | 34 (58%) | |
| Ethnicity | Blacks | 4(7%) |
| Whites | 13(22%) | |
| Asian | 11(19%) | |
| Hispanics | 30(51%) | |
| Unknown | 1(1%) | |
| Disease status | AP | 18(30%) |
| CP | 41(70%) | |
| Pre-transplant TKI use | Yes | 12 (20%) |
| No | 47 (80%) | |
| Graft source | BM | 9 (15%) |
| PBSC | 50 (85%) | |
| Female to male | Yes | 15 (75%) |
| No | 44 (25%) | |
| Donor CMV | Negative | 12 (20%) |
| Positive | 47 (80%) | |
| Recipient CMV | Negative | 9 (15%) |
| Positive | 50 (85%) | |
| aGVHD | Yes | 25 (42.4%) |
| No | 34 (57.6%) | |
| aGVHD grade II-IV | Yes | 17 (28.8%) |
| No | 42 (71.2%) | |
| cGVHD | Yes | 36 (61%) |
| No | 23 (39%) | |
| Grade of cGVHD | Extensive | 22 (37%) |
| Limited | 14 (23%) | |
| None | 23 (40%) | |
| IST>3 years | Yes | 14 (24%) |
| No | 43 (73%) | |
| Not available | 2 (3%) | |
| Outcome | Death | 20 (34%) |
| Alive | 39 (66%) | |
| Median time to death | Days (range) | 671 (88-2908) |
| Cause of death | Infection | 3 (15%) |
| Relapse | 16 (80%) | |
| Respiratory failure | 1 (5%) |
Abbreviations: AP: Advanced phase; CP: Chronic phase; CMV: Cytomegalovirus BM: bone marrow; PBSC, peripheral blood stem cell; aGVHD: acute graft versus host disease; cGVHD: chronic graft versus host disease; IST: immunosuppressive therapy; TKI: tyrosine kinase inhibitor